异常母血清筛查妊娠中染色体微阵列分析与非侵入性产前检测的比较
这项回顾性研究纳入2013至2021年因母血清筛查异常且超声正常的559例羊膜腔穿刺病例,发现21例(3.8%;95%CI 2.4-5.7%)有临床显著染色体微阵列分析结果。理论上正常NIPT后残留风险为2.0%(95%CI 1.1-3.6%),系统综述6篇文献4890例显示残留风险2.3%。作者认为此类妊娠应推荐侵入性检测而非NIPT。
要点
- 母血清筛查异常且超声正常者中临床显著CMA结果占3.8%(95%CI 2.4-5.7%)
- 理论上正常NIPT后CMA异常残留风险为2.0%(95%CI 1.1-3.6%)
- 作者认为此类妊娠应推荐侵入性检测而非NIPT
核心结论
- 母血清筛查高危妊娠在理论上正常NIPT后,每50例中可发现1例临床显著CMA结果,作者认为此类妊娠应推荐侵入性检测而非NIPT。
- 作者认为以NIPT作为一线筛查替代母血清筛查会漏诊不仅常见常染色体三体而且包括其他CMA可检测疾病的风险妊娠。
研究设计与样本
- 回顾性研究纳入2013至2021年因母血清筛查异常且超声结果正常的全部CMA检测。
- 与本地对照队列7235例母血清筛查及超声结果正常妊娠按母亲年龄分层比较临床显著CMA结果率。
- 系统综述检索自建库至2021年10月、无时间或语言限制,纳入考察母血清筛查异常妊娠CMA检出率的研究。
主要发现
- 559例因母血清筛查异常行羊膜腔穿刺者中,21例(3.8%;95%CI 2.4-5.7%)发现临床显著CMA结果。
- 理论上正常NIPT后CMA异常残留风险估计为2.0%(95%CI 1.1-3.6%)(1/50)。
- 母血清筛查异常且年龄小于35岁女性的残留风险显著高于低风险妊娠女性。
- 系统综述纳入6篇文章共4890例母血清筛查异常妊娠的CMA结果,理论上正常NIPT后CMA异常残留风险为2.3%。
临床怎么用
- 作者认为母血清筛查高危妊娠在理论上正常NIPT后应推荐侵入性检测而非NIPT。
- 作者认为以NIPT作为一线筛查替代母血清筛查会漏诊CMA可检测疾病的风险妊娠。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the effect of maternal age on the rate of clinically significant chromosomal microarray analysis results in pregnancies with abnormal maternal serum screening and to establish the residual risk for abnormal microarray findings after omitting noninvasive prenatal testing (NIPT)-detectable aberrations in pregnancies with abnormal maternal serum screening. METHODS: This retrospective study included all chromosomal microarray analysis tests performed in pregnancies with abnormal maternal serum screening and normal ultrasonogram results over the years 2013-2021. The rate of clinically significant (pathogenic and likely pathogenic) chromosomal microarray analysis findings was compared with a local control cohort of 7,235 pregnancies with normal maternal serum screening and ultrasonogram results, stratified by maternal age. Calculation of residual risk for clinically significant chromosomal microarray analysis results after normal NIPT was performed by omission of common NIPT-detectable anomalies. Systematic review for studies examining the yield of chromosomal microarray analysis in pregnancies with abnormal maternal serum screening was performed from inception to October 2021, with no time or language restrictions. RESULTS: Of the 559 amniocenteses performed due to abnormal maternal serum screening, 21 (3.8%; 95% CI 2.4-5.7%) clinically significant chromosomal microarray analysis results were found. The residual risk for chromosomal microarray analysis aberrations after theoretically normal NIPT was estimated to be 2.0% (95% CI 1.1-3.6%) (1/50) and was significantly higher for women younger than age 35 years with abnormal maternal serum screening, compared with women with low-risk pregnancies. Systematic review yielded six articles encompassing 4,890 chromosomal microarray analysis results in pregnancies with abnormal maternal serum screening, demonstrating 2.3% residual risk for chromosomal microarray analysis anomalies after theoretically normal NIPT. DISCUSSION: Clinically significant chromosomal microarray analysis findings can be found in 1 of every 50 pregnancies with high-risk maternal serum screening after theoretically normal NIPT, implying that invasive testing and not NIPT should be recommended in such pregnancies. In addition, NIPT use as a first-tier screening modality instead of maternal serum screening would miss pregnancies at increased risk not only for common autosomal trisomies but for additional chromosomal microarray analysis-detectable disorders.
引用
- Sagi-Dain L, Salzer Sheelo L, Brabbing-Goldstein D, et al. Chromosomal Microarray Analysis Compared With Noninvasive Prenatal Testing in Pregnancies With Abnormal Maternal Serum Screening. Obstet Gynecol. 2022. PMID: 35576346. doi:10.1097/AOG.0000000000004758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。